학술논문
The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS
Document Type
article
Author
Ioannis Grigoropoulos; Georgios Tsioulos; Artemis Kastrissianakis; Shiran Shapira; Orr Green; Vasiliki Rapti; Maria Tsakona; Thomas Konstantinos; Athina Savva; Dimitra Kavatha; Dimitrios Boumpas; Konstantinos Syrigos; Ioannis Xynogalas; Konstantinos Leontis; Vasileios Ntousopoulos; Vissaria Sakka; Zafeiris Sardelis; Andreas Fotiadis; Lamprini Vlassi; Chrysoula Kontogianni; Anastasia Levounets; Garyfalia Poulakou; Mina Gaga; Ronan MacLoughlin; Justin Stebbing; Nadir Arber; Anastasia Antoniadou; Sotirios Tsiodras
Source
Respiratory Research, Vol 25, Iss 1, Pp 1-13 (2024)
Subject
Language
English
ISSN
1465-993X
Abstract
Abstract Introduction EXO-CD24 are exosomes genetically manipulated to over-express Cluster of Differentiation (CD) 24. It consists of two breakthrough technologies: CD24, the drug, as a novel immunomodulator that is smarter than steroids without any side effects, and exosomes as the ideal natural drug carrier. Methods A randomized, single blind, dose-finding phase IIb trial in hospitalized patients with mild to moderate Coronavirus disease 2019 (COVID-19) related Acute Respiratory Distress Syndrome (ARDS) was carried out in two medical centers in Athens. Patients received either 109 or 1010 exosome particles of EXO-CD24, daily, for five consecutive days and monitored for 28 days. Efficacy was assessed at day 7 among 91 patients who underwent randomization. The outcome was also compared in a post-hoc analysis with an income control group (n = 202) that fit the inclusion and exclusion criteria. Results The mean age was 49.4 (± 13.2) years and 74.4% were male. By day 7, 83.7% showed improved respiratory signs and 64% had better oxygen saturation (SpO2) (p